Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

July 18, 2017July 18, 2017

Elderly Patients With Early-stage Lung Cancer Good Candidates For SBRT, Study Suggests

News

Elderly people with early-stage lung cancer might also benefit from stereotactic body radiation therapy (SBRT), finds a study of more than 1,000 patients. The study, “Stereotactic Body Radiation Therapy in Octo- ... Read more

June 22, 2017

Entinostat-Keytruda Clinical Trial in NSCLC Will Proceed to Next Stage

News

A clinical trial exploring entinostat in combination with Merck’s Keytruda (pembrolizumab) in non-small cell lung cancer (NSCLC) patients who progressed despite checkpoint-blocking treatment, met the required response threshold to advance ... Read more

June 20, 2017June 20, 2017

ASTRO Issues Guidelines for Using High-dose Focused Radiation in Early-stage Lung Cancer

News

The American Society for Radiation Oncology (ASTRO) has released new guidelines for treating inoperable lung cancer patients with stereotactic body radiation therapy (SBRT). Based on evidence from numerous studies and ... Read more

June 15, 2017

70% of Patients with Brain Cancer Originating in the Lungs Responded to Tagrisso, Trial Shows

News

Seventy percent of patients with brain cancer that originated in the lungs responded to treatment with Tagrisso (osimertinib), according to a Phase 3 clinical trial. That compared with 31 percent who ... Read more

May 9, 2017

Tagrisso Helps Lung Cancer Patients Whose Disease Resisted Other Therapies, Trial Shows

News

Tagrisso (osimertinib) was more effective than chemotherapy in treating lung cancer patients whose disease had progressed on another treatment, according to a Phase 3 clinical trial. Patients who took Tagrisso ... Read more

May 5, 2017May 5, 2017

Takeda’s Alunbrig Receives FDA Accelerated Approval for Treatment of ALK+ Lung Cancer

News

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Takeda‘s Alunbrig (brigatinib) to treat ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients who either progressed or could not ... Read more

February 14, 2017February 14, 2017

Study of Aggressive Lung Cancer Subtype May Pave Way for Targeted Treatment

News

All lung cancers are not created equal, a recent study demonstrated, showing that tumors classified as small cell lung cancer can look and behave in very specific ways. Since the ... Read more

December 15, 2016December 15, 2016

Lung Cancer Metastases Controlled by Molecular Actions in ‘Cellular Post Office’

News

A molecular signal in a cellular compartment often referred to as the cell’s “post office” explains how lung cancer cells gain the ability to leave the lung tissue and cause metastases ... Read more

December 6, 2016December 6, 2016

Sleep Apnea May Promote Lung Cancer by Triggering Tumor-friendly Agent

News

Sleep apnea, and the recurrent lack of oxygen that it causes, may promote lung cancer growth and the ability of the cancer to spread. Researchers found that occasional low-oxygen conditions make cancer ... Read more

December 1, 2016

Updated Prognostic Tool Predicts Survival in Lung Cancer Patients with Brain Metastases

News

Researchers updated a prognostic tool to assess survival in patients with lung cancer and brain metastases by adding new data of genetic and molecular changes in tumors. The updated tool, ... Read more